Trial Profile
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Registrational
- Acronyms pathfinder8
- Sponsors Novo Nordisk
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183952).
- 11 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Nov 2020 This trial has been completed in Norway according to European Clinical Trials Database record.